JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

IQVIA Holdings Inc

Закрыт

СекторЗдравоохранение

158.31 1.23

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

153.65

Макс.

159.91

Ключевые показатели

By Trading Economics

Доход

182M

514M

Продажи

264M

4.4B

P/E

Средняя по отрасли

20.898

67.147

Рентабельность продаж

11.778

Сотрудники

93,000

EBITDA

1B

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+43.33% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

5 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-12B

28B

Предыдущая цена открытия

157.08

Предыдущая цена закрытия

158.31

Новостные настроения

By Acuity

39%

61%

147 / 347 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

IQVIA Holdings Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

30 апр. 2026 г., 23:08 UTC

Отчет

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 апр. 2026 г., 23:07 UTC

Отчет

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 апр. 2026 г., 22:20 UTC

Отчет

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 апр. 2026 г., 23:48 UTC

Обсуждения рынка

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 апр. 2026 г., 23:47 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

30 апр. 2026 г., 23:47 UTC

Обсуждения рынка

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 апр. 2026 г., 23:27 UTC

Обсуждения рынка

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 апр. 2026 г., 23:22 UTC

Отчет

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 апр. 2026 г., 23:20 UTC

Обсуждения рынка

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 апр. 2026 г., 22:52 UTC

Отчет

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 апр. 2026 г., 22:33 UTC

Отчет

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 апр. 2026 г., 22:32 UTC

Отчет

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 апр. 2026 г., 22:32 UTC

Отчет

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 апр. 2026 г., 22:24 UTC

Приобретения, слияния, поглощения

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 апр. 2026 г., 22:23 UTC

Приобретения, слияния, поглощения

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 апр. 2026 г., 22:23 UTC

Приобретения, слияния, поглощения

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 апр. 2026 г., 22:23 UTC

Приобретения, слияния, поглощения

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 апр. 2026 г., 22:11 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

30 апр. 2026 г., 22:11 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

30 апр. 2026 г., 22:11 UTC

Обсуждения рынка

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 апр. 2026 г., 22:05 UTC

Отчет

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 апр. 2026 г., 21:57 UTC

Отчет

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 апр. 2026 г., 21:56 UTC

Отчет

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 апр. 2026 г., 21:56 UTC

Отчет

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 апр. 2026 г., 21:55 UTC

Отчет

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 апр. 2026 г., 21:54 UTC

Отчет

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 апр. 2026 г., 21:54 UTC

Отчет

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 апр. 2026 г., 21:53 UTC

Отчет

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 апр. 2026 г., 21:49 UTC

Отчет

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 апр. 2026 г., 21:49 UTC

Отчет

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Сравнение c конкурентами

Изменение цены

IQVIA Holdings Inc Прогноз

Целевая цена

By TipRanks

43.33% рост

Прогноз на 12 месяцев

Средняя 224.54 USD  43.33%

Максимум 255 USD

Минимум 185 USD

Основано на мнении 16 аналитиков Wall Street, спрогнозировавших целевые цены для IQVIA Holdings Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

16 ratings

14

Покупка

2

Удержание

0

Продажа

Техническая оценка

By Trading Central

150.68 / 153.45Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Neutral Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

147 / 347Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat